Full Breakdown
Indian Drugmakers Launch Cheaper Versions of Semaglutide
3/23/2026, 11:05:48 AM
Market Entry of Generic Semaglutide
In a significant development for diabetes and obesity treatment, at least six Indian generic drugmakers have introduced lower-cost versions of Novo Nordisk's blockbuster drugs, Ozempic and Wegovy, following the expiration of the patent for semaglutide in India. This event occurred over the weekend, with prices slashed by approximately 70%, making these treatments more accessible. Analysts predict that over 40 Indian companies will launch more than 50 variants of semaglutide, aiming to capture a share of the projected $100 billion global obesity market by the end of the decade.
Key Players and Their Offerings
Several major Indian pharmaceutical companies have already entered the market with their generic formulations:
- Sun Pharmaceutical has launched semaglutide injectables under the brand names Noveltreat and Sematrinity, priced between 900 to 2000 rupees ($9.58-$21.30) for weekly treatment.
- Dr. Reddy's Laboratories offers semaglutide under the brand name Obeda, available in 2 mg and 4 mg dose strengths, with a monthly cost of approximately 4200 rupees ($44.73).
- Zydus Lifesciences has introduced three brands—Semaglyn, Mashema, and Alterme—offering injectable semaglutide at an average monthly cost of around 2200 rupees ($23.43).
- Torrent Pharmaceuticals has launched both oral and injectable forms under the brand names Sembolic and Semalix, with injectable drugs starting at 3999 rupees ($42.59) per month.
- Glenmark Pharmaceuticals has released GLIPIQ in vial and pen formats, with monthly costs estimated between 1300 to 1760 rupees ($13.84-$18.74).
- Alkem Laboratories has introduced semaglutide under three brand names—Semasize, Obesema, and Hepaglide—starting at 1800 rupees ($19.17) per month.
Implications for the Healthcare Market
The influx of generic semaglutide is expected to significantly reduce treatment costs for patients in India and potentially in international markets, including Canada, Brazil, and Turkey. This move aligns with the broader trend of Indian pharmaceutical companies expanding their reach in the global market, particularly in the lucrative obesity treatment sector.
Criticism & Opposition
While the introduction of these generics is welcomed for its potential to lower costs, concerns have been raised regarding the quality and efficacy of the new products. Critics argue that the rapid market entry of multiple brands could lead to variability in treatment outcomes, emphasizing the need for stringent regulatory oversight to ensure patient safety.
Official Statements & Responses
Industry experts have noted the importance of this development in making diabetes and obesity treatments more affordable. A spokesperson from Sun Pharmaceutical stated, "Our goal is to provide effective treatment options at accessible prices." However, the regulatory bodies have yet to comment on the implications of this market shift.
What's Next
As more companies prepare to launch their versions of semaglutide, the Indian pharmaceutical landscape is poised for significant changes. Ongoing monitoring of product quality and patient outcomes will be essential as these generics become widely available.
